Arthritis therapeutic drug

A technology of arthritis and pharmacy, applied in the field of osteoarthritis, in the field of treatment of rheumatism or rheumatoid arthritis, can solve the problems of arthritis with insignificant curative effect, slow onset of effect, and small side effects

Inactive Publication Date: 2005-07-06
XIANGBEI WELMAN PHARMA CO LTD
View PDF1 Cites 14 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although there are many types of arthritis treatment drugs, there is still no definitive cure or control of arthritis, especially for rheumatoid, rheumatoid arthritis, and osteoarthritis.
Moreover, the currently commonly used non-steroidal anti-inflammatory drugs often have gastrointestinal side effects, and sometimes the curative effect on arthritis is not obvious, such as aniline drug acetaminophen, etc.; side effects, such as liver and kidney toxicity; although glucocorticoids are effective, they can cause serious adverse reactions such as infection, osteoporosis, and iatrogenic adrenal insufficiency, so they are not suitable for long-term use
Other therapeutic drugs also have shortcomings such as inaccurate curative effect, slow onset of effect, and large side effects.
[0015] To sum up, there is currently a lack of drugs on the market that have a rapid onset of action, relieve joint pain, and have few side effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Arthritis therapeutic drug
  • Arthritis therapeutic drug
  • Arthritis therapeutic drug

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0115] Suppositories for rectal administration may be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at intestinal temperature to dissolve and release the drug into the rectum, Such as cocoa butter or polyethylene glycols.

[0116] Solid dosage forms for oral administration are as described above, including powders, granules, tablets, pills and capsules. This dosage form can be prepared by mixing the active ingredient with at least one additive including sucrose, lactose, cellulose sugar, mannitol, maltose, dextran, starch, agar, alginic acid, chitin, chitosan , pectin, tragacanth, gum arabic, gelatin, collagen, casein, albumin and synthetic or semi-synthetic polymers and glycerides, generally these dosage forms may contain additional additives, including inert diluents, lubricants such as hard Magnesium fatty acid, preservatives such as parabens, sorbic acid, antioxidants such as vitamin C, alpha-tocoph...

Embodiment 1

[0127] The compound wedelolide is extracted from Eclipta alba.

[0128] (1) soaking and filtering

[0129] Eclipta whole grass 300kg, fully immersed in 0.75 tons of ethanol (concentration 95%)→soaked overnight (10 hours) and coarsely filtered to remove the whole grass residue (reserved) Net filtration (suction filtration) or high-speed centrifugation (10000rpm, 10 minutes ), thereby removing dust and fine residue green clarified filtrate.

[0130] (2) Ethanol recovery

[0131] Recover ethanol by distillation, the temperature does not exceed 60 degrees Celsius every 2 hours, remove the extract in the reaction kettle to the collection bucket (the extract is dark dark green, slightly viscous) and repeat the above steps until all the ethanol is recovered.

[0132] (3) Second soaking and back distillation

[0133] Recover 0.75 tons of ethanol, re-soak the whole herb residue and soak overnight, and the coarse filtration, net filtration and distillation recovery requirements are t...

Embodiment 2

[0145] Inhibitory effect of the compound wedelolide on xylene-induced ear inflammation in mice

[0146] Experimental animals: Kunming mice, weighing 18-22g.

[0147] Administration method: intraperitoneal injection, the doses of wedelolide are 12.5 mg / kg and 25 mg / kg respectively, the negative control group is 0.5% CMC, and the positive control group ibuprofen, the dose is 25 mg / kg.

[0148] Experimental method: Animals were randomly divided into 4 groups according to body weight, 10 animals in each group. The mice were continuously given the test substance for 4 days, and 1 hour after the administration on the fourth day, 50 μl of xylene was evenly applied to both sides of the right ear of the mouse, and the left ear was left untreated. After being left for 2 hours, the mice were killed by dislocation, and ear pieces from the same position of both ears were taken out with a punch with an inner diameter of 8 mm, and weighed. The difference in the weight of the left and right...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a tonka bean ethers compound extracted from Compositae plants, the pharmaceutical composition containing the composition, and the use in treating antirheumatic or rheumatoid arthritis, and osteoarthritis. Extracorporal and animal in vivo experiment shows that, the compound can effectively treat and improve the symptoms for these diseases.

Description

technical field [0001] The invention relates to a coumarin compound extracted from Compositae plants, a pharmaceutical composition or health care product containing the compound, and its application in treating rheumatic or rheumatoid arthritis and osteoarthritis. Background technique [0002] Arthritis refers to the inflammation of the joints, the etiology of which is complex, and the onset of various forms. But rheumatoid arthritis and osteoarthritis are the most common. Rheumatoid arthritis is a common disease characterized by chronic polyarticular inflammation, which is characterized by chronic, progressive, symmetrical and erosive peripheral joint damage, and the pathological changes are joint synovial cell proliferation, expansion, Hyperemia, hypertrophy of blood vessel walls, inflammatory cell infiltration, fibrous tissue hyperplasia, hyaline, degeneration, etc., may be accompanied by extra-articular systemic damage. The pathogenesis of rheumatoid arthritis is not y...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/366A61K31/37A61K36/00A61K36/28A61P19/02A61P29/00C07D493/04
CPCA61K31/366A61K31/37A61K36/28A61P19/02A61P29/00
Inventor 俞强张怡轩张婷周文亮
Owner XIANGBEI WELMAN PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap